Research programme: pain therapeutics - Axxam

Drug Profile

Research programme: pain therapeutics - Axxam

Alternative Names: BKR1 antagonist - Axxam; CB2 agonist - Axxam; Nav 1.7 blocker - Axxam; TRPM8 blocker - Axxam

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axxam; Newron Pharmaceuticals; Primm srl; University of Milan Bicocca
  • Developer Axxam; Newron Pharmaceuticals
  • Class
  • Mechanism of Action Bradykinin B1 receptor antagonists; Cannabinoid receptor CB2 agonists; Nav1.7-voltage-gated-sodium-channel-inhibitors; Purinergic P2X7 receptor antagonists; TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Pain in Italy
  • 02 Feb 2011 Early research is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top